STRATEGIES TO REDUCE PRESCRIPTION OPIOID MISUSE IN THE USA

Jody L. Green, PhD

Director of Research Administration

Denver Health & Hospital Authority, Denver CO USA

23 November 2013



US Prescription Opioid Misuse: The Facts

More Americans die every year from drug overdose than motor vehicle accidents <u>http://wonder.cdc.gov</u>

In 2010:

- motor vehicle traffic deaths 33,687
- poisoning deaths 42,917


<u>drug</u> poisoning deaths 38,329

>opioid overdose deaths 16,651 (43%)

Surveillance of Prescription Drug Misuse: US RADARS[®] System

- Researched Abuse, Diverted and Addiction-Related Surveillance (RADARS) System
- Conducting prescription drug abuse, misuse and diversion surveillance in the United States since 2001
- Provide common ground for Industry, Regulatory Agencies, Academics and Clinicians

United States RADARS® System Mosaic Approach



Strategies Employed




Others: Pill Mills, Law Enforcement, Prevention, Education, Harm Reduction

Strategy: Abuse Deterrent Formulations


- **Physical/Chemical barriers** –prevent chewing, crushing, cutting, grating, or grinding. Resist extraction of the opioid using common solvents like water, alcohol, or other organic solvents.
- **Agonist/Antagonist combinations** –opioid antagonist added to interfere with, reduce, or defeat the euphoria associated with abuse. The antagonist can be sequestered and released only upon manipulation of the product.
- Aversion Substances combined to produce unpleasant effect if dosage form is manipulated prior to ingestion or a higher dosage than directed is used.
- **Delivery System** (including depot injectable formulations and implants) –drug release designs or method of drug delivery that offers resistance to abuse.
- **Prodrug** –lacks opioid activity until transformed in the gastrointestinal tract can be unattractive for intravenous injection or intranasal routes of abuse.

Poison Center Intentional Exposures, Population Rate OxyContin®, Opana® ER, Other Opioids




Year/Quarter


Poison Center Intentional <u>Abuse</u>, Population Rate OxyContin®, Opana® ER, Other Opioids




Poison Center Intentional Exposures, URDD Rate OxyContin®, Opana® ER, Other Opioids




Poison Center Intentional <u>Abuse</u>, URDD Rate OxyContin®, Opana® ER, Other Opioids



Treatment Programs, URDD Rate OxyContin®, Opana® ER, Other Opioids




Drug Diversion, URDD Rate OxyContin®, Opana® ER, Other Opioids



Strategy: Abuse Deterrent Formulations

Effective in reducing non-oral abuse of specific product Reduction of inappropriately prescribing Less desirable for misuse Retains pain medication efficacy



- Little/no impact on oral misuse Does not prevent physical dependence or addiction to active ingredient
- Not required on all prescription opioids = limited effect
- **Risk of defeating ADF technology**

Strategy: Prescription Drug Monitoring Programs


Statewide electronic databases of prescriptions dispensed for controlled substances (i.e., prescription drugs of abuse that are subject to stricter government regulation)

Large variation between programs (data architecture, ownership, use, compliance)

Strategy: Prescription Drug Monitoring Programs Used by

- prescribers to check individual patient's history with controlled substances during medical management to support access and legitimate medical use
- pharmacy boards to monitor prescriber behavior
- pharmaceutical companies to monitor inappropriate prescriber behavior and target interventions
- law enforcement to target efforts in combatting diversion
- researchers to study emerging trends and impact of interventions
- regulatory agencies to inform public health initiatives

PDMPs Operational in 43 States



Source: National Association of Model State Drug Laws Last updated 9/11/2012; accessed 9/15/2012

Strategy: Prescription Drug Monitoring Programs

- 2012 review article summarized all peer-reviewed research published between 2001 and 2011 (11 articles; not all addressed effectiveness).
 - Concluded that PDMPs reduce "doctor shopping," change prescribing behavior, and reduce prescription drug abuse.
- RADARS System Study Published 2012



Pain Medicine 2012; 13: 434–442 Wiley Periodicals, Inc.


OPIOIDS, SUBSTANCE ABUSE & ADDICTIONS SECTION

Original Research Article

Do Prescription Monitoring Programs Impact State Trends in Opioid Abuse/Misuse? Figure 1 Prescription monitoring program (PMP) status summary of states reporting to the RADARS System Poison Center Program, first quarter of 2003 through third quarter of 2009.


Key Findings:

- PC intentional exposures increased 1.9% per quarter w/o PMP, 0.2% w/PDMP (p=0.036)
- Treatment increased 4.9% per quarter w/o PMP, 2.6% w/PDMP (p=0.058)



Strategy: Abuse Deterrent Formulations

Effective in reducing abuse Combats "doctor shopping" Changes prescribing behavior Rate of increase slower in states w/PDMP



State-based variation; no interstate integration (yet)

Not all PDMPs cover hydrocodone, codeine, and tramadol

Cannot account for all sources of supply


Require prescriber to submit a query

Strategy: Risk Evaluation & Mitigation Strategy

Risk Evaluation and Mitigation Strategies (REMS)

- Product specific, shared or class-wide
- Purpose to implement actions that prevent and mitigate risk of a particular drug
- Actions may include:
 - Medication guide for patients risks and prevention (i.e. accidental exposures in children)
 - Call center for patients and providers
 - Provider training and certification BEFORE they are able to prescribe the drug
 - Limitations on how many patients or prescriptions each provider may have
 - Patient registries
 - Monitoring of REMs activities


Pediatric Accidental Exposures




Strategy: Community Based Interventions

Operation UNITE

- "Unlawful Narcotics Investigations, Treatment and Education"
- Three-pronged intervention
 - Education
 - Enforcement
 - Treatment



Rise in Abuse Less in Targeted Region




Strategy: Community Based Interventions

Effective in reducing rate of incline in abuse in targeted area

Target interventions developed for specific issues in specific areas

Smaller population usually means more homogenous population reducing confounders



Limited impact by geographic region

Sustainability

Can be expensive for little return Require community engagement


REVIEW OF OPIOID AND STIMULANT TRENDS IN THE UNITED STATES

Have we reached the plateau?

Overall Opioid Abuse Trends in United States Population Rates, 2002-2012


Population Rate

Availability Rate (URDD)




The RADARS® System

Poison Center Program – Abuse Exposures Population Rate – All Opioids 2009 Q1 through 2013 Q2




The RADARS® System Opioids

Poison Center Program – Abuse Exp - Pop Rate by Drug 2009 Q1 through 2013 Q2




The RADARS® System

Poison Center Program – Abuse Exposures URDD Rate – All Opioids 2009 Q1 through 2013 Q2




The RADARS® System Opioids

Poison Center Program – Abuse Exp - URDD Rate by Drug 2009 Q1 through 2013 Q2




The RADARS® System

Treatment Programs– URDD Rate – All Opioids 2009 Q1 through 2013 Q2




The RADARS® System Opioids

Treatment Programs– URDD Rate by Drug 2009 Q1 through 2013 Q2




The RADARS® System

Drug Diversion Program – URDD Rate – All Opioids 2009 Q1 through 2013 Q2



The RADARS® System Opioids

Drug Diversion Program – URDD Rate by Drug 2009 Q1 through 2013 Q2



What the Future Holds

- Pharmaceutical innovations
 - Active ingredients and abuse deterrent platforms
- Regulatory strategies
 - Integration of Prescription Drug Monitoring Programs
 - Guidance on requirements for labeling of abuse deterrent formulations (incentives for companies to develop technology)
 - Requirement of additional post market studies (observational and clinical trials)
- Measuring impact
 - Multimodal ("mosaic") approach
- Global Movement

D0610.1111/bqt.12138

BJCP British Journal of Clinical Pharmacology

Letter to the Editors

Prescription opioid abuse in the UK

Isabelle Giraudon,¹ Karen Lowitz,² Paul I. Dar

'Health Consequences, Prevalence, Consequences and Data Man Addiction (EMCDDA), Lisbon, Portugal, 'Rocky Mountain Poison (Denver, CO, USA and 'Medical Toxicology Office – Guy's and St Ti




Figure 1

Drug-related deaths by selected drugs reported in England, Wales and Scotland, 2001–2011. Note that heroin and morphine are reported as one category in the data from England, Wales and Scotland; given that the focus of this analysis is on prescription opioids, that category was not included in this analysis. ——, methadone in England and Wales; <u>—</u>, tramadol in England and Wales; <u>—</u>, other opiate in England and Wales; ______, England and Wales; <u>—</u>, other opiate in England and Wales; _______, England and Wales; <u>______</u>, other opiate in England and Wales; _______, England and Wales; <u>______</u>, other opiate in England and Wales; _______, England and Wales; <u>______</u>, other opiate in England in Scotland;

Global Movement

The National (Dubai UAE) Thursday, November 23, 2013

lationa **Deals to give** Al Ain global presti aerospace

arget of 20,000 jobs in sector by 2

Bosnian children given earlier start

Youths illegally using scription drugs

HG

Thank you for your Loyalty

Youths illegally using prescription drugs

Boys found with pills such as tramadol, ministry figures show

Mohammed N Al Khan

DUBAI // Boys as young as 12 have been found illegally using prescription drugs including tramadol, Ministry of Interior statistics show. Last year 131 cases of drug use in boys under the age of 18 were reported, including one aged 13. That was down from 2011 when 153 boys were found, including one aged 12 and five aged 13.

None of the cases involved girls. "These numbers reflect cases that have come to the attention of the

ministry," said Col Abdul Rahman Al Owais, deputy director general of the ministry's anti-narcotics directorate. "They don't take into account recurring offenders. That said, it shows just how prevalent this problem is in the country."

He was addressing the fourth annual International Security Education conference yesterday.

Boris Znamenski, programme management officer for the UN Office on Drugs and Crime, told the conference education was the key to preventing drug use.

"Punishment does not give the best results," Mr Znamenski said.

"More police on the street will not result in less drugs. If the demand is there, you will have supply."

Drugs, continued on 6 ->

RADARS[®] System Europe Mosaic Approach

